NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

A Message to Weary Longs: Why I Still Believe NWBO Has Likely Received Positive MHRA Signals

Let me be blunt: a lot of people on this board are exhausted, and I don’t blame them. The wait has been long, the silence is maddening, and the skeptics love to fill that vacuum with doom. But at some point, you must stop staring at the silence and start looking at the actions. Because NWBO’s actions are not subtle. They’re not ambiguous. They’re not “maybe someday” gestures. They are the actions of a company that already knows where this is heading. NWBO is engaging in concrete, capital-intensive, operationally irreversible decisions that a severely cash-strapped microcap simply cannot justify unless they’ve received strong, positive, non-public signals from the MHRA.

Let’s start with the obvious: NWBO does not have the financial cushion to gamble. With ~$1–2M in cash, heavy liabilities, and a going-concern warning, they don’t have the luxury of throwing money at speculative infrastructure. Every move they make has to be tied to something real. Yet look at what they’ve done anyway.

They committed to a dedicated leukapheresis clinic at London Welbeck Hospital — not a temporary trial setup, but a permanent, commercial-grade facility designed to handle patient volume and even external clients. That is not a “hope” move. That is a “we’re going to need this” move.

Then there’s the Grade C expansion at Sawston, which more than doubles capacity and is explicitly commercial. Grade C is not for R&D. It’s for throughput. It’s for scale. It’s for product that’s going to market. And NWBO is building it out while sitting on barely enough cash to run payroll. That alone should tell you something.

But the biggest tell — the one skeptics never want to address — is the U.S. tech transfer. Tech transfer is expensive, complicated, and irreversible. You don’t do it unless you expect to be producing commercial product. A company in NWBO’s financial condition does not take on that burden unless they believe approval is coming.

And it doesn’t stop there. They’re integrating Flaskworks/Eden automation, which is only needed when you’re planning for thousands of patients, not dozens. They’re negotiating a second UK manufacturing site, which only makes sense if they expect volume beyond what Sawston can handle. Advent is training new facilities, both in the UK and the U.S., and training is the last step before commercial production. You don’t train multiple sites unless you’re preparing for a real launch.

And then, most recently, they brought in Dr. Annalisa Jenkins — someone with global R&D leadership at Merck Serono, senior roles at BMS (both companies’ products were trialed with DCVax-L… coincidence?), a biotech CEO background, and even service on the FDA Science Board. This is not a symbolic hire. This is someone you bring in when you’re preparing for the final regulatory stretch and the transition into commercialization. A company with NWBO’s balance sheet does not bring in someone of her caliber unless they believe they’re going to need her expertise (and Dr. Jenkins would not have accepted the position without believing likewise).

When you put all of this together, the idea that NWBO is just “hoping” for approval becomes laughable. These are post-approval actions happening before the approval announcement. And that only happens when a company has received strong, positive, non-public signals from the regulator — the kind of signals that say, “Make sure you’re ready.” Regulators never say “you’re approved” ahead of time. But they absolutely give late-stage cues about manufacturing readiness, supply-chain planning, post-approval obligations, and commercial-scale validation. NWBO’s actions match those cues point for point.

So yes, the wait is long. Yes, the silence is frustrating. But the company’s behavior is telling a very different story than the skeptics are. NWBO is not acting like a company guessing. They’re acting like a company preparing for the inevitable.

If you’re tired, I get it. But don’t ignore what’s right in front of us. The signals are there. And they’re louder than the wait, the silence, or the skeptics.